PepGen Inc. (PEPG) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PepGen Inc. (PEPG) Healthcare & Pipeline Overview

PepGen Inc. is a clinical-stage biotechnology company specializing in oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Their lead candidate, PGN-EDO51, targets Duchenne muscular dystrophy (DMD) and is currently in Phase I trials, positioning them in a competitive landscape focused on genetic medicines.

What Is the Investment Thesis for PEPG?

PepGen Inc. presents a focused investment opportunity within the biotechnology sector, specifically in the area of oligonucleotide therapeutics for neuromuscular and neurologic diseases. The primary value driver is the clinical progress of PGN-EDO51, their lead candidate for Duchenne muscular dystrophy (DMD), currently in Phase I trials. Positive clinical data could significantly increase the company's valuation. Further potential lies in the development of PGN-EDODM1 for myotonic dystrophy type 1 (DM1) and other pipeline candidates. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other companies developing therapies for the same indications. With a market cap of $210M and a beta of 2.34, PEPG represents a high-risk, high-reward investment profile.

Based on FMP financials and quantitative analysis

PEPG Key Highlights

PGN-EDO51, PepGen's lead product candidate, is currently in Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD).

• PepGen is developing PGN-EDODM1 for the treatment of myotonic dystrophy type 1 (DM1), expanding their therapeutic pipeline.
• The company's technology focuses on Enhanced Delivery Oligonucleotides (EDOs) to improve the efficacy and safety of oligonucleotide-based therapies.
• PepGen was founded in 2018, indicating a relatively young company in the competitive biotechnology landscape.
• The company's market capitalization is $0.12 billion as of May 9, 2026.

Who Are PEPG's Competitors?

PEPG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PEPG's Key Strengths?

Proprietary EDO technology platform enhances drug delivery.

• Lead product candidate PGN-EDO51 in Phase I clinical trials for DMD.
• Experienced management team with expertise in oligonucleotide therapeutics.
• Focus on addressing unmet medical needs in rare neuromuscular diseases.

What Are PEPG's Weaknesses?

Clinical-stage company with no currently approved products.

• High cash burn rate associated with clinical development activities.
• Reliance on the success of a limited number of pipeline candidates.
• Small market capitalization, making it vulnerable to market fluctuations.

What Could Drive PEPG Stock Higher?

Announcement of Phase I clinical trial results for PGN-EDO51 in DMD patients.

• Initiation of clinical trials for PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
• Progress in preclinical development of PGN-EDO53, PGN-EDO45, and PGN-EDO44 for DMD.
• Potential for strategic partnerships and collaborations to accelerate pipeline development.

What Are the Key Risks for PEPG?

Financial-distress signal — its Altman Z-Score of 1.08 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-59.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for PGN-EDO51 or other pipeline candidates.
• Competition from other companies developing therapies for DMD and DM1.
• Regulatory hurdles and potential rejection of drug candidates.
• High cash burn rate associated with clinical development activities.
• Reliance on the success of a limited number of pipeline candidates.

What Are the Growth Opportunities for PEPG?

• Expansion of the DMD Pipeline: PepGen has the opportunity to expand its DMD pipeline beyond PGN-EDO51. The company is developing PGN-EDO53, PGN-EDO45, and PGN-EDO44, all targeting different exon-skipping approaches for the treatment of DMD. Each of these candidates represents a distinct market opportunity within the broader DMD treatment landscape. Positive preclinical and clinical data from these programs could significantly increase PepGen's market value and attract partnerships. The timeline for these programs will depend on successful preclinical development and regulatory approvals, with potential for new clinical trials starting within the next 2-3 years.
• Advancement of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1): PGN-EDODM1 represents a significant growth opportunity for PepGen in the treatment of DM1. Successful development and commercialization of PGN-EDODM1 would expand PepGen's therapeutic focus beyond DMD and address a significant unmet medical need in DM1. The DM1 market is estimated to grow substantially over the next decade, driven by increased diagnosis and the development of targeted therapies. Clinical trials for PGN-EDODM1 are expected to progress over the next 3-5 years, potentially leading to regulatory approval and market launch.
• Strategic Partnerships and Collaborations: PepGen can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates. Partnering with larger pharmaceutical companies or specialized biotechnology firms could provide access to additional resources, expertise, and funding. These collaborations can also help PepGen expand its geographic reach and market access. Potential partnership opportunities could arise within the next 1-2 years as PepGen's clinical programs advance and generate more data.
• Expansion into New Therapeutic Areas: While PepGen's initial focus is on neuromuscular and neurologic diseases, the company's EDO platform has the potential to be applied to other therapeutic areas. Expanding into new areas, such as oncology or rare genetic disorders, could significantly broaden PepGen's market opportunity and diversify its pipeline. This expansion would require additional research and development efforts, but could yield substantial long-term growth. The timeline for entering new therapeutic areas is likely 3-5 years, contingent on successful preclinical studies and proof-of-concept data.
• Geographic Expansion: PepGen currently operates primarily in the United States. Expanding into international markets, such as Europe and Asia, represents a significant growth opportunity. These markets offer access to a larger patient population and potentially faster regulatory pathways in some regions. Establishing a presence in these markets would require strategic planning, regulatory approvals, and partnerships with local distributors. The timeline for geographic expansion is estimated at 2-4 years, depending on regulatory requirements and market entry strategies.

What Are PEPG's Competitive Advantages?

• Proprietary EDO (Enhanced Delivery Oligonucleotide) technology platform.
• Strong intellectual property portfolio protecting their drug candidates and technologies.
• Clinical-stage pipeline with lead candidate PGN-EDO51 in Phase I trials.
• Expertise in oligonucleotide chemistry and drug development.
• Focus on addressing unmet medical needs in rare neuromuscular and neurologic diseases.

What Does PEPG Do?

Founded in 2018 and headquartered in Cambridge, Massachusetts, PepGen Inc. is dedicated to developing innovative oligonucleotide therapeutics aimed at treating severe neuromuscular and neurologic diseases. The company's core technology revolves around Enhanced Delivery Oligonucleotides (EDOs), which are designed to improve the efficacy and safety of oligonucleotide-based therapies. PepGen's lead product candidate, PGN-EDO51, is an EDO peptide currently undergoing Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of the dystrophin protein. Beyond PGN-EDO51, PepGen is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1 (DM1), a disease characterized by muscle weakness, myotonia (prolonged muscle contraction), and a variety of other symptoms. Additionally, the company is advancing a pipeline of other EDO therapeutic candidates, including PGN-EDO53, PGN-EDO45, and PGN-EDO44, all targeting different exon-skipping approaches for the treatment of DMD. PepGen's focus is on addressing the underlying genetic causes of these debilitating diseases through targeted therapies.

What Products and Services Does PEPG Offer?

• Develop oligonucleotide therapeutics for neuromuscular diseases.
• Focus on treating severe genetic disorders like Duchenne muscular dystrophy (DMD).
• Utilize Enhanced Delivery Oligonucleotides (EDOs) to improve drug efficacy.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
• Develop therapies targeting the underlying genetic causes of diseases.
• Advance a pipeline of EDO therapeutic candidates for DMD and other conditions.
• Research and develop innovative approaches to oligonucleotide-based therapies.
• Address unmet medical needs in the treatment of neuromuscular and neurologic disorders.

How Does PEPG Make Money?

• Develop and patent novel oligonucleotide therapeutics.
• Conduct preclinical and clinical research to validate drug candidates.
• Seek regulatory approval from agencies like the FDA.
• Potentially commercialize approved therapies directly or through partnerships.
• Generate revenue through product sales, licensing agreements, and collaborations.

What Industry Does PEPG Operate In?

PepGen Inc. operates within the competitive biotechnology industry, specifically targeting neuromuscular and neurologic diseases. The market for genetic therapies is experiencing rapid growth, driven by advancements in oligonucleotide technologies and a greater understanding of disease mechanisms. Competition includes companies developing similar therapies for DMD and DM1, such as Sarepta Therapeutics and Biogen. The success of PepGen depends on demonstrating the superior efficacy and safety of its EDO platform compared to existing and emerging treatments.

Who Are PEPG's Key Customers?

• Patients with Duchenne muscular dystrophy (DMD).
• Patients with myotonic dystrophy type 1 (DM1).
• Healthcare providers who treat patients with neuromuscular diseases.
• Pharmaceutical companies interested in licensing or acquiring novel therapies.
• Research institutions and academic centers involved in clinical trials.

Company Profile

PepGen Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO James McArthur. PEPG has traded publicly since 2022.

How PepGen Inc. Is Valued

PepGen Inc. carries a market capitalization of $210M, placing it in the micro-cap category. Relative to its peer group, PEPG's quantitative score of 47/100 is below the peer average of 73/100.

Return on equity for PepGen Inc. stands at -59.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -49.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -63.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 14.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -63.1%, the inverse of the P/E and a quick read on earnings relative to price.

PepGen Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.08 places it in the distress zone, a signal of elevated financial risk.

PepGen Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 13.1% above estimates on average.

Wall Street analysts project PepGen Inc. revenue of about $37.5M for fiscal 2026, with EPS near $-1.11. The estimate reflects 7 contributing analysts.

PEPG Financials

PEPG Latest News

No recent news available for PEPG.

PEPG Analyst Consensus

PEPG MoonshotScore

Latest PepGen Inc. Analysis

Common Questions About PEPG (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources